Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P033. Drugs used in the treatment of fistulae in Crohn's disease preserve mesenchymal stem cell survival
P033. Neutrophil gelatinase-associated lipocalin (NGAL): A potential biomarker in IBD
P033. Serum hepcidin expression varies with disease activity in Crohn's disease
Authors:

R. Chinnathuri1, D. Ward2, L. Nichols3, C. Tselepis2, T. Iqbal1, 1Queen ELizabeth Hospital, Gastroenterology Unit, Birmingham, United Kingdom, 2University of Birmingham, Cancer Studies, Birmingham, United Kingdom, 3University of Birmingham, Primary Care, Birmingham, United Kingdom

P033

Expression of aryl hydrocarbon receptors (AHR) in the condition of experimental acute ileitis and administrations simvastatin and antagonist of receptors in interlekin-1

Authors:

A. Kamyshny*1, A. Zherebiatiev2

1ZSMU, Microbiology, Zaporozhye, Ukraine, 2Zaporozhye State Medical University, Microbiology, Zaporozhye , Ukraine

P034.

Preliminary evidence for a role of the renin angiotensin system in intestinal fibrosis in Crohn's disease using angiotensin receptor immunohistochemistry

Authors:

S. Ray1,2, J. Soeda1, J. Oben1,2, J. Sanderson2,3, 1University College London, Institute of Liver & Digestive Health, London, United Kingdom, 2Guy's & St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, 3King's College London, Department of Nutritional Sciences, London, United Kingdom

P034. Disruption of the intestinal barrier through M1 macrophages – relevance for IBD?
P034. Serum concentration of estrogen is associated with inflammatory bowel disease activity
Authors:

P.M. Linares1, M. Chaparro1, A. Algaba2, J.P. Gisbert1, M. Guijarro Rojas3, F. Bermejo2, A.C. Urzainqui-Mayayo4, M.E. Fernández-Contreras1, 1Hospital Universitario de la Princesa-IP, Gastroenterology and CIBEREHD, Madrid, Spain, 2Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain, 3Hospital Universitario de la Princesa-IP, Pathology, Madrid, Spain, 4Hospital Universitario de la Princesa-IP, Immunology, Madrid, Spain

P034. The hypoxia adaptive response regulates metallothionein expression in intestinal epithelial cells
P034

The IBD-Cope: A new instrument for measuring coping in Inflammatory Bowel Disease patients

Authors:

A. McCombie*1, A. Swaminathan2, R. Mulder1, R. Gearry3

1University of Otago, Medicine, Christchurch, New Zealand, 2University of Otago, Christchurch Hospital, Department of Medicine and Gastroenterology, Christchurch, New Zealand, 3University of Otago, Christchurch Hospital, Medicine and Gastroenterology, Christchurch, New Zealand

P035. Linking TNFα inhibitors and Notch-1: Novel implications in inflammatory bowel diseases
P035. New compounds against ulcerative colitis through molecular topology
P035. Salicin ameliorates the inflammation and prevents the loss of gut flora in DSS induced mice model of colitis
Authors:

N.V. Nirmal Verma1, J.P. Jaishree Paul2, 1Jawaharlal Nehru University, School of Life Sciences, New Delhi, India, 2Jawahrlal Nehru University, School of Life Sciences, New Delhi, India

P035

Comparative structural, functional, nonclinical, and phase 1 similarity assessments of PF-06438179, a potential biosimilar to infliximab, and marketed reference products

Authors:

J.E. McClellan*1, C. Udata2, D. Yin2, S. Salts3, T.R. Johnson4, M. Derzi5, M. Bolt5, H.D. Conlon6, C.F. Kirchhoff7, L.G. Lorello8, J. McNally9, M.I. Rehman10

1Pfizer Inc., Biosimilars Research and Development Unit, New York, NY, United States, 2Pfizer Inc., Clinical Pharmacology, San Diego, CA , United States, 3Pfizer Inc., Clinician, San Diego, CA , United States, 4Pfizer Inc., Pharmacokinetics, Dynamics and Metabolism, San Diego, CA , United States, 5Pfizer Inc., Drug Safety Research & Development, Andover, MA , United States, 6Pfizer Inc., Analytical Research & Development, Andover, MA , United States, 7Pfizer Inc., Global Technology Services Biomanufacturing Sciences, Chesterfield, MO, United States, 8Pfizer Inc., Pharmacokinetics, Dynamics and Metabolism, Groton, CT, United States, 9Pfizer Inc., Pharmacokinetics, Dynamics and Metabolism, Andover, MA , United States, 10Pfizer Inc., Biosimilars Research, Cambridge, MA, United States

P036.

Polyfunctionality of human gut-homing CD4 T cells

Authors:

A.N. Hegazy, A. Datsi, H. Uhlig, F. Powrie, John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, United Kingdom

P036. Increase in dendritic cell migration markers CCR7 and CCR9 in the neo-terminal ileum of postoperative Crohn's disease: An adaptive response to bacterial exposure?
P036. Involvement of gut macrophages in the fibrogenic process in Crohn's disease
P036. SPARC affects colorectal tumourigenesis
Authors:

K. Fu1, F. Lloyd1, C. Forrest2, B. Klopcic1, I. Lawrance1, 1University of Western Australia, Centre for Inflammatory Bowel Disesases, Medicine and Pharmacology, Perth, Australia, 2University of Western Australia, Pathology and Laboratory Medicine, Perth, Australia

P036

Apoptotic neutrophils ameliorate intestinal inflammation - possible mechanism of granulocyte/monocyte apheresis

Authors:

S. Ishihara1, K. Kawashima*1, H. Sonoyama1, Y. Tada1, A. Oka1, R. Kusunoki1, N. Fukuba1, N. Oshima1, I. Moriyama2, T. Yuki3, H. Maegawa4, N. Kashiwagi4, Y. Kinoshita1

1Shimane University Faculty of Medicine, Internal Medicine II, Izumo, Japan, 2Shimane University Hospital, Cancer center, Izumo, Japan, 3Shimane University Hospital, Gastrointestinal Endoscopy, Izumo, Japan, 4JIMRO Co., Ltd, Research division, Takasaki, Japan

P037.

Neutralization of CTLA-4 alleviates murine DSS-induced colitis through changing Th17-Treg profile

Authors:

B. Xia, S. Huang, Zhongnan Hospital of Wuhan University School of Medicine, Department of Gastroenterology, Wuhan, China

P037. Bench-top-MR-imaging as a method to monitor acute experimental colitis in a mouse model